Abstract
Cangelosi et al sought to evaluate the prognostic value of the level of Nucleolin (NCL) mRNA expression in neuroblastoma, and its potential clinical utility in risk stratification.1 They provided evidence that NCL is an independent (adjusting for age, INSS stage, MYCN status) novel prognostic biomarker. This research is significant because prognostic biomarkers are used to assign patients with neuroblastoma to the appropriate level of therapeutic intensity. In cooperative groups like Children's Oncology Group and International Society for Pediatric Oncology-Neuroblastoma, and throughout the world, treating physicians follow validated risk stratification (‘classifiers’) based on biomarkers that are prognostic of survival, to assign patients to low-, intermediate-, and high-risk groups.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
